Beyond the Basics – Lower-Risk Myelodysplastic Syndromes
Saeed Sadeghi, MD, discusses a case of lower-risk myelodysplastic syndromes (LR-MDS), focusing on the mechanisms of action for luspatercept vs epoetin alfa, insights from the COMMANDS study, real-world data on treatment outcomes, health care resource utilization, and future directions in anemia management within this patient population.
EP. 1: Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS
September 30th 2024Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these differences may correlate with clinical benefits for patients with lower-risk myelodysplastic syndromes (LR-MDS).
Watch
